BioCryst (BCRX) director Jill C. Milne files Form 3 reporting no share ownership

Rhea-AI Filing Summary

BioCryst Pharmaceuticals director files initial ownership report showing no holdings

BioCryst Pharmaceuticals Inc. director Jill C. Milne filed an initial ownership report on Form 3 for the company’s common stock. The filing states that no non-derivative or derivative securities are beneficially owned, meaning she reports no current ownership position in BioCryst shares or related equity instruments.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Milne Jill C.

(Last) (First) (Middle)

4505 EMPEROR BLVD

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/23/2026

3. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Alane P. Barnes, by power of attorney	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 3 for BCRX disclose about Jill C. Milne?

The Form 3 reports that director Jill C. Milne currently has no beneficial ownership of BioCryst Pharmaceuticals securities. Both non-derivative and derivative holdings tables are effectively empty, and the remarks section confirms no securities are beneficially owned.

Does Jill C. Milne own any BioCryst Pharmaceuticals (BCRX) shares?

According to the Form 3, no securities are beneficially owned by Jill C. Milne. This covers both direct and indirect ownership, as well as any derivative securities like options, warrants, or convertible instruments tied to BioCryst stock.

What is the event date for Jill C. Milne’s Form 3 at BCRX?

The Form 3 lists 01/23/2026 as the date of the event requiring the statement. This is typically when the person became a director or otherwise subject to Section 16 reporting for BioCryst Pharmaceuticals securities.

What is Jill C. Milne’s relationship to BioCryst Pharmaceuticals (BCRX)?

The filing identifies Jill C. Milne as a director of BioCryst Pharmaceuticals Inc. She is not reported as an officer or a 10% owner, and the form is filed by one reporting person only.

Are there any derivative securities reported for Jill C. Milne in BCRX?

No. The Form 3’s derivative securities section does not list any options, warrants, or other derivatives. The remarks explicitly state that no securities are beneficially owned, confirming the absence of derivative positions.